Johnson & Johnson

Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace innovation—bringing ideas, products and services to life to advance the health and well-being of people around the world. We believe in collaboration, and that has led to breakthrough after breakthrough, from medical miracles that have changed lives, to the simple consumer products that make every day a little better.

Employees of the Johnson & Johnson Family of Companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

Our Family of Companies comprises:

  • The world’s sixth-largest consumer health company
  • The world’s largest and most diverse medical devices company
  • The world’s sixth-largest biologics company
  • And the world’s fifth-largest pharmaceuticals company

We have more than 265 operating companies in more than 60 countries.

Company Growth (employees)
New Brunswick, US
Size (employees)
126,400 (est)
Johnson & Johnson was founded in 1886 and is headquartered in New Brunswick, US

Key People at Johnson & Johnson

Alex Gorsky

Alex Gorsky

Dominic J. Caruso

Dominic J. Caruso

Ronald A. Williams

Ronald A. Williams

Independent Director
Michael Sneed

Michael Sneed

VP, Global Corporate Affairs
Peter Fasolo

Peter Fasolo

Executive VP, CHRO
Paul Stoffels

Paul Stoffels

Executive VP & CSO

Johnson & Johnson Office Locations

Johnson & Johnson has office in New Brunswick
New Brunswick, US

Johnson & Johnson Metrics

Johnson & Johnson Summary

Market capitalization

$346.3 b

Closing share price

Johnson & Johnson's current market capitalization is $346.3 b.

Johnson & Johnson Financials

Johnson & Johnson's revenue is $71.9 b in FY, 2016 which is a 2.6% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016


$71.3 b$74.3 b$70.1 b$71.9 b

Revenue growth, %


Cost of goods sold

$22.3 b$22.7 b$21.5 b

Gross profit

$49 b$51.6 b$48.5 b

Gross profit Margin, %


Sales and marketing expense

$21.8 b$22 b$21.2 b

R&D expense

$8.2 b$8.5 b$9 b

Operating expense total

$30 b$30.4 b$30.2 b

Depreciation and amortization

$4.1 b$3.9 b$3.7 b


$16.4 b$21.6 b$19.2 b

Interest expense

$482 m$533 m$552 m

Interest income

($74 m)($67 m)($128 m)

Income tax expense

$1.6 b$4.2 b$3.8 b

Net Income

$13.8 b$16.3 b$15.4 b$16.5 b

Operating cash flow

$17.4 b$18.5 b$19.3 b

Johnson & Johnson Operating Metrics

Y, 2014Y, 2015

Ongoing Phase III Programs


Discovery Projects


Drugs Approved by FDA


Johnson & Johnson Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Actelion PharmaceuticalsJanuary 26, 2017$30 b
Abott Medical OpticsSeptember 16, 2016$4.3 b
Vogue InternationalJune 02, 2016$3.3 b
Novira TherapeuticsNovember 08, 2015
XO1March 20, 2015
Alios BioPharmaSeptember 30, 2014$1.8 b
Aragon PharmaceuticalsJune 17, 2013$1 b

Johnson & Johnson Market Value History

Johnson & Johnson Revenue Breakdown

Johnson & Johnson Online Presence

Johnson & Johnson Company Life

You may also be interested in